Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma (Q33383721)

26 July 2017

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma (English)

1 reference

26 July 2017

phase I clinical trial

0 references

0 references

14

Henry S Friedman

1 reference

26 July 2017

9

Darell D Bigner

1 reference

26 July 2017

7

Sridharan Gururangan

1 reference

26 July 2017

4

Annick Desjardins

1 reference

26 July 2017

8

Allan H Friedman

1 reference

26 July 2017

3

David A Reardon

1 reference

26 July 2017

11

Roger E McLendon

1 reference

26 July 2017

6

Jeremy N Rich

1 reference

26 July 2017

1

Jennifer A Quinn

1 reference

26 July 2017

2

Sara Xiaoyin Jiang

1 reference

26 July 2017

5

James J Vredenburgh

1 reference

26 July 2017

12

James E Herndon

1 reference

26 July 2017

John H Sampson

10

1 reference

PubMed ID

19289491

26 July 2017

Amy Walker

series ordinal

13

1 reference

26 July 2017

16 March 2009

1 reference

26 July 2017

1 reference

26 July 2017

11

1 reference

26 July 2017

5

1 reference

26 July 2017

556-561

1 reference

Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Activity of temozolomide in the treatment of central nervous system tumor xenografts

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Response criteria for phase II studies of supratentorial malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765345

Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19289491

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1215/15228517-2009-007

1 reference

release_q2mteu7b2recxnnlqnlsb23ymy

26 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q2mteu7b2recxnnlqnlsb23ymy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMCID

2765345

1 reference

26 July 2017

1 reference

PubMed ID

19289491